When does the ibrutinib patent expire?
Ibrutinib (Imbruvica) is protected by multiple patents and exclusivity periods, so there is not a single “one-date” answer. The practical “expiration” date depends on which specific patent is being considered (drug substance, formulation, or method-of-use) and what additional regulatory exclusivity applies in each country.
For a consolidated look at relevant filings and expected end-of-exclusivity timelines for specific markets, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/ (search for “ibrutinib” there).
What does DrugPatentWatch.com show for ibrutinib?
DrugPatentWatch.com tracks patent and exclusivity status for individual drugs, typically listing:
- Patent numbers (and sometimes assignees)
- Jurisdictions (such as the US and EU, depending on the entry)
- Expected patent expiry or key end dates tied to specific protections
Because ibrutinib has a long commercialization history, different patents can fall away at different times, meaning competition may begin once the earliest blocking protection expires for a given claim scope and geography.
Does exclusivity end the same time as the last patent?
Often, no. Even if one patent expires, other patents (for example, formulation or additional therapeutic use) can continue to block generic or biosimilar entry. Separately, regulatory exclusivities (which vary by country) can add time beyond the first patent expiry.
That is why you’ll usually see a staggered timeline rather than a single expiration day.
Where are you located (US, EU, UK, etc.)?
Patent expiry dates differ by jurisdiction because patent terms, filings, and regulatory exclusivity rules vary. If you tell me the country or region you care about, I can narrow the answer to the most relevant “end date(s)” to look for.